Bedrijfsoverzicht
Dermata Therapeutics, Inc. is a late-stage medical dermatology entity dedicated to the identification, development, and commercialization of pharmaceutical product candidates designed for the treatment of medical skin diseases and aesthetic applications. The company operates within the healthcare sector, specifically the biotechnology industry, a classification that signifies its focus on innovative biological products and therapies rather than traditional small-molecule drugs or medical devices. As of the latest data, the organization employs approximately nine individuals and maintains a market capitalization of $4.91 million. These financial figures indicate that the company is a micro-cap entity with very limited scale relative to established pharmaceutical peers, suggesting a high degree of operational risk and a reliance on successful clinical outcomes to expand its business model significantly.
Financiële gezondheid
Dermata Therapeutics reported no revenue over the trailing twelve-month period, resulting in a net loss of $-7,558,557 and an EBITDA figure that is not available due to the absence of operating income. The significant gap between the reported revenue (which is effectively zero) and the substantial net loss reveals a cost structure dominated by research and development expenditures, general administrative costs, and potentially clinical trial expenses, all of which are expensed before any sales revenue is realized. The company generated free cash flow of $-5,016,645 during the trailing twelve months, indicating a continuous burn rate that requires ongoing capital infusion to sustain operations and advance its product pipeline. Despite the negative cash flow, the balance sheet demonstrates liquidity with cash reserves totaling $7.52 million, while the company carries zero debt, creating a distinct contrast between cash assets and liabilities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved commercial sales to generate a positive contribution margin from operations. The current ratio stands at 4.79, which indicates a strong short-term liquidity position where current assets significantly exceed current liabilities, providing a comfortable buffer for meeting obligations. However, the return on equity is -194.2% and the return on assets is -85.3%, metrics that reveal that management's effectiveness in generating profit from shareholder capital and total assets is currently negative due to the lack of earnings and the ongoing investment phase of the business.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A because the company has not reported positive earnings, while the forward P/E is -0.32, a metric that is typically not meaningful for loss-making biotechnology firms and implies expectations of future profitability that have not yet materialized in historical data. The price-to-book ratio is 0.52, indicating that the market values the company's equity at approximately half of its book value, which often suggests that investors are pricing in the high risk of development failure or that the company's intangible assets are not fully captured on the balance sheet. The price-to-sales ratio is N/A as there are no sales, and the EV/EBITDA is N/A, meaning these alternative valuation metrics cannot be applied to assess relative value in the traditional sense for a pre-revenue entity. Over the past year, the stock price has ranged between a low of $1.10 and a high of $9.90, with the current trading price positioned within this historical volatility range but requiring real-time data to determine the exact percentage distance from these extremes. The beta value is 0.50, which indicates that the stock's price volatility is roughly half that of the broader market, suggesting lower systematic risk but also potentially lower liquidity and higher sensitivity to specific biotechnology sector news.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's pre-revenue status where traditional growth rate metrics are not applicable in a comparative annual sense. Because the company has not generated revenue, there are no earnings to grow faster or slower than revenue; the focus remains entirely on the successful execution of clinical trials to transition from a loss-making R&D phase to a profitable commercial stage. As a non-dividend payer, the company pays no dividends and maintains a dividend yield of N/A, while the payout ratio is 0.0%, confirming that all available financial resources are being reinvested directly into research and development activities rather than distributed to shareholders. The overall growth and income profile is characterized by a total absence of current revenue generation and income distribution, relying instead on the potential for future value creation from its lead product candidate, XYNGARI, which is currently in Phase 3 clinical development.